DPT
N,N-dipropyltryptamine
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
DPT (N,N-dipropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is a close structural analog of DMT, yet is orally active without a monoamine oxidase inhibitor. It activates serotonin receptors and simultaneously floods the brain with stored serotonin[1][2] — a dual mechanism shared by no other classical psychedelic.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, 2C-T-7, LSD +2 moreDOI, 2C-T-7, LSD, psilocybin, mescaline show less
DPT was first synthesized in the early 1950s during a systematic study of tryptamine compounds.[3] Controlled clinical trials followed in the 1970s, using DPT to treat alcoholism and end-of-life psychological distress.[4][5] It remains federally unscheduled in the United States and has reappeared on research chemical markets, with forensic identification confirmed as recently as March 2025.[6]
Subjective effects include geometric visual patterns, emotional warmth, a dissolving sense of self, deep introspective states, and heightened interpersonal connection. The experience blends classical psychedelic hallucination with empathogenic openness — clinical investigators consistently noted both qualities together,[4] distinguishing DPT from more purely visionary substances. Anxiety, nausea, and disorientation are characteristic unsought effects.
DPT does not produce physical dependence, and no pharmacological lethal dose has been established.[7] The primary risks are seizure at high doses and a life-threatening reaction when combined with MAO inhibitors or antidepressants, which amplify DPT's serotonin release to toxic levels.safety citation needed No human pharmacokinetic studies exist — understanding rests on 1970s clinical trials, animal studies, and a single case report.
History[edit]
Discovery
DPT was first synthesized in the early 1950s during a systematic exploration of tryptamine analogs.[3] Animal testing confirmed pharmacological activity in 1954,[8] and human psychedelic properties were established during the 1960s.[9] It first appeared as a designer drug by 1968.
Clinical research
The only controlled clinical studies of DPT were conducted at the Maryland Psychiatric Research Center between 1973 and 1980. Researchers including Stanislav Grof, Richard Soskin, and William Richards used DPT within structured therapeutic sessions to treat alcoholism and end-of-life psychological distress.[4][5] No clinical trials have been conducted since.
Regulatory history and modern re-emergence
DPT remains federally unscheduled in the United States as of 2026. The DEA proposed scheduling it in January 2022 but withdrew the proposal that July. It has reappeared on research chemical markets, with forensic identification confirmed as recently as March 2025.[6]
The name dipropyltryptamine describes the compound's structure directly: two n-propyl chains on the tryptamine nitrogen. It circulates almost exclusively under the abbreviation DPT in both research literature and drug culture, with no widely established street names.
Chemistry[edit]
N,N-Dipropyltryptamine belongs to the substituted tryptamine family, sharing the indole-ethylamine backbone found in DMT, psilocin, and serotonin itself. Its molecular formula is C₁₆H₂₄N₂ (244.37 g/mol).
DPT differs from DMT only in that two n-propyl groups replace DMT's two methyl groups at the nitrogen — a change that makes DPT more resistant to enzymatic breakdown and more lipophilic,[11] enabling oral activity without a monoamine oxidase inhibitor. DPT contains no stereocenters and has not been found to occur in any living organism.[8]
Pharmacology[edit]
Mechanism of action
DPT produces its psychedelic effects primarily by activating serotonin receptors in the brain.[1] Blocking those receptors completely eliminates DPT's behavioral effects — confirmed across mice, rats, and primates.[12][13][14]
DPT also enters serotonin-releasing neurons through the SERT and displaces stored serotonin into the synapse[2] — a mechanism more typical of MDMA than classical psychedelics. This dual action — receptor activation plus serotonin release — places DPT pharmacologically between purely visionary psychedelics and empathogen-type drugs.[15]
Pharmacokinetics
No human pharmacokinetic studies have been published for DPT. The oral dose required to produce effects is far higher than the intramuscular dose used in clinical studies,[16][4][5] indicating the liver breaks down a substantial fraction before it reaches the brain. Effects last roughly 20 minutes when smoked, 3–5 hours when insufflated, and 2–4 hours when taken orally.[16]
Neuroscience[edit]
Where it acts
No direct human brain imaging studies of DPT have been published. Based on its confirmed serotonin receptor activation, DPT is expected to act on prefrontal cortex neurons that filter incoming sensory and cognitive signals — particularly the network involved in self-referential thought.
DPT's serotonin release through the transporter[2] adds a neurochemical dimension absent in purely receptor-driven psychedelics like DMT. This flood of synaptic serotonin likely contributes to the empathogenic quality — heightened emotional expressiveness and deepened interpersonal connection — consistently documented in clinical settings.[4]
Why it matters
Current neuroscientific models predict that DPT's serotonin receptor activation temporarily loosens the brain's tendency to filter experience through prior expectations, allowing suppressed emotional and sensory information to surface more freely. The profound self-exploration and emotional breakthroughs documented in clinical studies[5] fit this framework well.
DPT's dose-dependent seizure effects remain mechanistically unexplained. At low doses it prevents seizures; at higher doses it triggers them — and neither serotonin receptor blockade nor sigma-1 receptor blockade prevents the anticonvulsant effect.[1]
Subjective Effects[edit]
DPT blends the visual intensity of a classical psychedelic with a warmth and emotional openness more typical of empathogens.[2] The two qualities coexist rather than alternate — vivid color and pattern arrive alongside a genuine softening of emotional distance. The resulting character is simultaneously visionary and intimate.
DPT sits between DMT and MDMA in felt character: more emotionally textured than DMT's raw visionary intensity, more hallucinatory than MDMA's warmth.[15] Compared to psilocybin, the body feel is heavier and the empathogenic quality more pronounced.[4]
Effect Grid
At common oral doses (~100–175 mg), the full psychedelic experience emerges. Visual hallucinations include bright bursts of light, geometric patterning overlaying surfaces, and tunnel-like visions. Enhanced emotional expressiveness and deepened self-exploration become prominent — the therapeutic qualities leveraged in the 1970s MPRC clinical studies. Time distortion is significant. Thought acceleration and novel associative thinking are typical.
Physically, pupil dilation is pronounced. Cardiovascular stimulation (elevated heart rate, blood pressure) is expected as a class effect. Body load ranges from a warm, diffuse sensation to noticeable muscular tension. Nausea is possible during onset.
Sleep is not possible during the active phase. Full commitment time is 4–6 hours including aftereffects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Ganzfeld effect · Environmental patterning · Symmetrical texture repetition · Tracers · Color enhancement · Visual morphing · After-images · Visual haze / noise · Music enhancement · Spatial disorientation · Auditory distortion · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Visual melting · Visual magnification · Vestibular distortion · Auditory misinterpretation · Peripheral vision distortion · Proprioceptive distortion · Sound sensitivity · Touch enhancement · Visual diffraction · Synesthesia · Dreaming enhancement · Peripheral misidentification · Visual acuity enhancement · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Auditory hallucinations · Visual scenery slicing · Object activation · Perspective hallucinations · Shadow people · Visual flipping · Olfactory hallucination · Persisting hallucinations
Tracers · Color enhancement · Visual morphing · After-images · Visual haze / noise · Music enhancement · Spatial disorientation · Auditory distortion · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Perspective distortion · Visual melting · Visual magnification · Vestibular distortion · Auditory misinterpretation · Peripheral vision distortion · Proprioceptive distortion · Sound sensitivity · Touch enhancement · Visual diffraction · Synesthesia · Dreaming enhancement · Peripheral misidentification · Visual acuity enhancement · Olfactory enhancement · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Auditory hallucinations · Visual scenery slicing · Object activation · Perspective hallucinations · Shadow people · Visual flipping · Olfactory hallucination · Persisting hallucinations
Wakefulness · Body high · Body schema distortion · Muscle tension · Stimulation · Physical fatigue · Vibrations / buzzing · Nausea · Appetite suppression · Dizziness · Heart rate perception changes · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Insomnia · Involuntary body movements · Kundalini-like energy · Restlessness · Tactile euphoria · Temperature dysregulation · Trembling · Dehydration sensation · Headache · Bodily lightness · Laughter fits · Nystagmus (eye wobbles) · Respiratory stimulation · Vasoconstriction · Yawning · Sexual arousal enhancement · Bruxism · Diarrhea · Muscle relaxation · Nasal congestion · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Muscle tension · Stimulation · Physical fatigue · Vibrations / buzzing · Nausea · Appetite suppression · Dizziness · Heart rate perception changes · Tingling / electric sensations · Bodily heaviness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Insomnia · Involuntary body movements · Kundalini-like energy · Restlessness · Tactile euphoria · Trembling · Dehydration sensation · Headache · Bodily lightness · Laughter fits · Nystagmus (eye wobbles) · Respiratory stimulation · Vasoconstriction · Yawning · Sexual arousal enhancement · Bruxism · Diarrhea · Muscle relaxation · Nasal congestion · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Confusion · Thought disorganization · Cognitive impairment · Focus suppression · Introspection enhancement · Pattern recognition enhancement · Language suppression · Multiple thought streams · Thought loops · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Information processing suppression · Openness enhancement · Thought connectivity · Cognitive euphoria · Cognitive flexibility · Increased nature relatedness · Memory fragmentation · Motivation suppression · Thought acceleration · Creativity enhancement · Memory replays · Synchronicity · Humor enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Information processing enhancement · Amnesia · Delirium · Delusions
Focus suppression · Introspection enhancement · Pattern recognition enhancement · Language suppression · Multiple thought streams · Thought loops · Memory suppression · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Information processing suppression · Openness enhancement · Thought connectivity · Cognitive euphoria · Cognitive flexibility · Increased nature relatedness · Memory fragmentation · Motivation suppression · Thought acceleration · Creativity enhancement · Memory replays · Synchronicity · Humor enhancement · Thought deceleration · Analysis enhancement · Focus enhancement · Information processing enhancement · Delirium · Delusions
Emotional lability · Simultaneous emotions · Catharsis · Euphoria · Empathy enhancement · Irritability
Empathy enhancement · Irritability
Social disconnection · Sociability suppression · Disinhibition · Automaticity · Ego inflation · Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Ego inflation · Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Transpersonal visions · Death-rebirth sequence · Near-death experience · Non-dual awareness · Cessation · Transpersonal memory access · Voidness
Cessation · Transpersonal memory access · Voidness
Timeline
First alerts emerge as subtle mood shift and mild perceptual brightening. A gentle body awareness develops, centered in the abdomen.
Visual effects begin — color saturation increases, surfaces may breathe or shift. Emotional sensitivity heightens noticeably. Mild nausea is possible during this phase.
Full psychedelic intensity: vivid geometric hallucinations, bright bursts of light, tunnel-like visions. Emotional depth and self-exploration reach maximum. Time distortion is pronounced.
Visual effects gradually recede. Emotional intensity softens but introspective thinking often continues. Physical tension releases progressively.
Residual mood elevation, enhanced emotional openness, and mild perceptual sensitivity may persist. Cognitive integration of the experience often continues during this phase.
⚠ Do not drive or operate machinery for at least 6 hours after ingestion, as residual perceptual and cognitive effects may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · 2C-T-7 · LSD
Toxicity
No lethal dose has been established for DPT in any species. The toxic threshold in humans is unknown.
Fatal case
The one published fatality involved a 20-year-old male who insufflated an unknown quantity of DPT.[7] He progressed from visual hallucinations to collapse, seizure, and vomiting within roughly two hours, and died 21 hours later despite advanced life support.
Seizure risk
DPT has dose-dependent effects on seizure threshold.[1] In animal models, low doses prevent seizures; at roughly double that dose, DPT itself triggers them. The single fatal case involved a seizure approximately two hours after insufflation,[7] consistent with high-dose proconvulsant risk.
Heart and circulation
No DPT-specific cardiovascular data exist. As a drug that activates serotonin receptors and releases serotonin into the synapse, DPT is expected to raise blood pressure and heart rate.safety citation needed
Psychological risks
Acute anxiety and psychological distress are predictable risks, consistent with all serotonergic psychedelics. Clinical studies reported low rates of serious adverse effects in supervised settings.[4][5]
Anxiety is a documented effect.[6] People with a personal or family history of psychosis may be at higher risk for triggering psychotic episodes — a risk shared by the psychedelic class.safety citation needed No DPT-specific data on lasting perceptual disturbances exist; class-level risk is acknowledged.[6]
Tolerance & dependence
DPT does not build tolerance to its own effects in animal studies — an unusual finding that contrasts sharply with other psychedelic classes.[17] Animals tolerant to other psychedelics do show reduced response to DPT, indicating one-way cross-tolerance.[17]
DPT is not considered habit-forming.[12] No dependence, self-administration, or withdrawal data have been published.
Drug interactions
DPT activates serotonin receptors directly and simultaneously releases stored serotonin into the synapse. Any drug that adds more serotonin to the system stacks on top of this dual effect.
MAO inhibitors are the most dangerous combination — they block the enzyme that breaks down serotonin, so DPT's serotonin release produces toxic concentrations that can cause a life-threatening overheating and seizure response.safety citation needed SSRIs and SNRIs block serotonin clearance and add to the same overload.safety citation needed Other serotonergic psychedelics produce additive effects in animal models,[18] and drugs that block a secondary serotonin receptor may intensify DPT's hallucinogenic effects.[12]
Contraindications
Based on DPT's pharmacology and the available evidence, the following conditions contraindicate use:
- Seizure disorders — DPT is proconvulsant at high doses in animals[1] and the single fatal case involved seizure[7]
- Concurrent MAO inhibitor use — the combination creates pharmacological grounds for life-threatening serotonin overloadsafety citation needed
- Personal or family history of psychotic disorders or bipolar disorder — class-level risk from serotonin receptor activationsafety citation needed
- Uncontrolled high blood pressure or heart conditions — expected cardiovascular stimulationsafety citation needed
- Pregnancy and breastfeeding — no safety data exist
Harm Reduction[edit]
Forms & Identification
DPT circulates as both the hydrochloride salt (white crystalline solid)[16] and the free base (oily liquid).[6] Both are visually indistinguishable from many other compounds, so reagent testing is necessary. A positive test confirms identity — not purity, potency, or safety.
Weigh every dose on a milligram-precision scale. No human pharmacokinetic data exist, meaning dose-response relationships are poorly understood even for accurately identified material.
Guidelines
- Test all material with appropriate reagent kits before use
- Use a milligram-precision scale for every dose — never estimate
- Start with a low dose and wait for full onset before considering redosing
- Have a sober, trusted companion present, especially at higher doses
- Choose a physically safe, comfortable environment with access to water and fresh air
- Avoid eating heavily for 2–3 hours before an oral dose to reduce nausea
- Clear the schedule for the full duration plus several hours of recovery
- Do not combine with monoamine oxidase inhibitors, SSRIs, SNRIs, or other serotonergic drugs
Set & Setting
DPT's empathogenic-psychedelic blend makes it unusually sensitive to emotional context. Clinical researchers administered it only within structured therapeutic frameworks with extensive preparation,[4] and the outcomes reflected how much set and setting mattered.
A calm, familiar environment with a trusted sober companion is important, particularly at higher doses. Avoid high-stakes situations and unresolved interpersonal conflict. Smoked and insufflated routes produce rapid onset that can be disorienting without preparation.
Aftercare & integration. DPT's empathogenic qualities frequently surface emotionally charged material. Allow time for quiet reflection in the hours and days following a session. Journaling while details remain fresh can help organize insights.
The clinical researchers who worked with DPT embedded it in a psychotherapeutic framework for good reason — the emotional content it produces benefits from structured processing. If the experience raised difficult emotions or memories, consider speaking with a therapist experienced in psychedelic integration. Peer integration circles can also provide support.
Resume normal obligations only when feeling grounded. Avoid major decisions in the immediate aftermath.
Recovery & Support
DPT is not considered physically addictive and does not produce dependence or withdrawal. Problematic patterns of use with any psychedelic can still develop — particularly as a means of avoiding difficult emotions rather than processing them.
If use has become compulsive or is interfering with daily functioning, support is available through psychedelic-informed therapists, harm reduction organizations such as the Fireside Project (62-FIRESIDE), and peer support communities. SAMHSA's National Helpline (1-800-662-4357) provides free referrals to local treatment services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The transition from uncomfortable to dangerous centers on seizure. Warning signs include sudden muscle rigidity, rhythmic jerking, loss of consciousness, or inability to respond. Severe confusion, chest pain, or extremely rapid heartbeat also warrant immediate help.
Immediate steps:
- Call emergency services immediately if seizure, loss of consciousness, or breathing difficulty occurs
- If the person is seizing, clear the area around them — do not restrain them or place anything in their mouth
- After a seizure stops, place the person in the recovery position (on their side) to prevent aspiration if vomiting occurs
- Do not induce vomiting
- Stay with the person and monitor breathing until help arrives
What to tell the dispatcher: Name the substance (DPT / dipropyltryptamine), the approximate amount and route if known, the time of consumption, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for DPT or any serotonergic psychedelic. Treatment is supportive.
Legal Status[edit]
DPT is federally unscheduled in the United States and Canada, while controlled in the United Kingdom, several EU member states, Japan, and New Zealand.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | Not on DEA Schedule I–V. Federal Analogue Act may apply if intended for human consumption. DEA proposed scheduling in January 2022, withdrew July 2022[19] |
| United States (Florida) | Schedule I | Illegal to buy, sell, or possess[19] |
| United States (Maine) | Schedule X | Equivalent to Schedule I; illegal[19] |
| Canada | Unscheduled | Not specifically listed under Controlled Drugs and Substances Act as of 2025citation needed |
| United Kingdom | Class A | Controlled under Misuse of Drugs Act 1971; tryptamine clause covers compounds structurally derived from tryptamine with alkyl substitutions[19] |
| Portugal | Table II-A | Listed alongside MDMA and LSD[19] |
| Belgium | Most restrictive category | Approximately equivalent to US Schedule II[19] |
| Greece | Controlled | Since February 18, 2003[19] |
| Japan | Designated Substance | Under Pharmaceutical Affairs Law; possession and sale prohibited[19] |
| Sweden | Controlled | Since January 26, 2016; manufacturing, trade, and possession prohibited[19] |
| New Zealand | Class C | As DMT analog under Misuse of Drugs Act[8] |
| Australia | Likely controlled (unconfirmed) | Not specifically confirmed as Schedule 9; likely covered as DMT analog under broad tryptamine provisionscitation needed |
Analog act considerations
In the United States, DPT's structural similarity to DMT (Schedule I) makes it potentially subject to the Federal Analogue Act, which treats structurally similar substances as equivalent when intended for human consumption.[19] DPT differs from DMT only in alkyl chain length — a difference likely within the scope of the structural similarity criterion.
references
- [1]
- [2] ^abcdCozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. — Journal of neural transmission doi:10.1007/s00702-009-0308-8
- [3]
- [4]
- [5]
- [6]